Health Blueprint

Masters of Longevity - The Pulse

Feature20 Oct 2026

MOTS-c: Where the Evidence Ends

Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?

MOTS-c: Where the Evidence Ends

By The Peptide Dosing editorial team

Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?

Feature20 Oct 2026
Abstract illustration of mitochondria with folded inner membranes in a cell

Editorial Picks

More from MoL
Conceptual amber glass heart within a translucent teal torso, illustrating an organ within its surrounding body.

How Old Is a Transplanted Heart?

By Marcel Achermann

Science Brief05 Oct 2026

Conceptual biomedical lab scene with AI research-agent panels connecting literature, hypothesis planning and experiment analysis to an automated pipetting station and a scientist at a microscope; not experimental data.

Anthropic’s Claude Phage Finding and the New Pace of Research

By Marcel Achermann

Commentary24 Sept 2026

Three global-health professionals examine a city map and interconnected images of neighbourhoods, services and care settings in a research workspace.

What Global Dementia Risk Models Still Miss

By Marcel Achermann

Science Brief24 Sept 2026

Older woman practising a controlled heel-to-toe balance step beside a sturdy chair at home, with a small unbranded supplement jar on a side table.

Calcium, Vitamin D and Fall Prevention: What the Evidence Changes

By Marcel Achermann

Science Brief22 Sept 2026

Conceptual cross-section of human hippocampal tissue with support cells, microglia-like cells and folded chromatin inside a cell nucleus.

What Changes in the Human Hippocampus with Age?

By Marcel Achermann

Editorial20 Sept 2026

Conceptual glass DNA helix and separate building blocks in a dark laboratory-inspired scene.

Nucleotides and Longevity: Is the Evidence Ready?

By Marcel Achermann

Editorial17 Sept 2026

Trending News

Based on last 48h engagement

  1. 01Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia (Nature - Biotechn...Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemiaNature - Biotechnology • 23 Oct 2026External link, opens in a new tab
  2. 02Fight Aging! Newsletter, October 26th 2026 (Fight Aging!)Fight Aging! Newsletter, October 26th 2026Fight Aging! • 25 Oct 2026External link, opens in a new tab
  3. 03Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO (PR Newswire)Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMOPR Newswire • 25 Oct 2026External link, opens in a new tab
  4. 04The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneous... (PR Newswire)The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of MedicinePR Newswire • 25 Oct 2026External link, opens in a new tab
  5. 05Holographic focused ultrasound enables multitarget EV and MSC delivery for neurovascular repair after ischemic stroke (Nature - Biotechnology)Holographic focused ultrasound enables multitarget EV and MSC delivery for neurovascular repair after ischemic strokeNature - Biotechnology • 25 Oct 2026External link, opens in a new tab

Upcoming Events

View calendar
  1. THE LIVE Barcelona 2026 (Barcelona, Spain)26. OCT 2026 - 28. OCT 2026THE LIVE Barcelona 2026Media PartnerSummit - Barcelona, Spain★
  2. CEE Longevity Summit & Retreat 2026 (Samorin, Slovakia)29. OCT 2026 - 31. OCT 2026CEE Longevity Summit & Retreat 2026Retreat - Samorin, Slovakia
  3. Parkhotel Longevity Retreat — October 2026 (Bad Bayersoien, Germany)31. OCT 2026 - 8. NOV 2026Parkhotel Longevity Retreat — October 2026Retreat - Bad Bayersoien, Germany
  4. Biology of Aging Symposium V 2026: The Possibilities of Aging and Health (Montreal, Canada)1. NOV 2026 - 3. NOV 2026Biology of Aging Symposium V 2026: The Possibilities of Aging and HealthConference - Montreal, Canada
  5. Atlas Cove Longevity Residency — November 2026 (Setúbal, Portugal)1. NOV 2026 - 6. NOV 2026Atlas Cove Longevity Residency — November 2026Retreat - Setúbal, Portugal

Latest in Longevity

|←←→
Youtube — Andrew Huberman22 Oct 2026
Essentials: Developing a Rational Approach to Supplementation for Health & Performance (Youtube — Andrew Huberman)

Essentials: Developing a Rational Approach to Supplementation for Health & Performance

The speaker, Andrew Huberman, recommended prioritizing habits and nutrition before considering supplements for health and performance.

Key takeaways
  • The speaker says habits and nutrition are the foundation.
  • The speaker says supplement choices are shaped by goals and diet.
  • A human lifespan benefit from supplements remains unproven here.
Startupticker.ch22 Oct 2026
AIFIF backs Four Promising Projects Emerging from Geneva’s Academic Institutions (Startupticker.ch)

Juturna Bio receives CHF 50,000 grant for brain-aging research

FIF granted Juturna Bio CHF 50,000 to support epigenetic reprogramming proof‑of‑concept in ageing brain cells.

Key takeaways
  • Juturna Bio is developing epigenetic approaches for ageing brain cells.
  • The grant supports early research, not a proven clinical treatment.
  • Alzheimer's disease was named as the project's initial target.
Longevity Docs News22 Oct 2026
Fusion startup Marathon pitches itself as an actinium-225 supplier for radiopharma (Longevity Docs News)

Fusion startup Marathon pitches itself as an actinium-225 supplier for radiopharma

Marathon Fusion proposes producing actinium-225 for cancer therapies using a planned reactor. Its yield claims rely on models.

Key takeaways
  • Yield claims are based on models, not an operating reactor.
  • Isotope shortages have constrained access to targeted cancer therapies.
  • Drug-grade production still has chemistry, purity and regulatory hurdles.
Neuroscience News21 Oct 2026
Cancer Drug Halts Fragile Brain Bleeds (Neuroscience News)

Cancer Drug Halts Fragile Brain Bleeds

Dabrafenib reduced brain vascular lesions and leakage in cell and mouse models of cerebral cavernous malformation.

Key takeaways
  • Benefit in human patients remains unproven by these preclinical findings.
  • Dabrafenib reduced lesion size and number in mouse models.
  • The drug restored cell junctions and reduced vessel leakage.